Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Chrissa Sioka, Andreas Fotopoulos & Athanassios P Kyritsis. (2014) Paraneoplastic immune-mediated neurological effects of systemic cancers. Expert Review of Clinical Immunology 10:5, pages 621-630.
Read now
Read now
Sabine Lindquist & Martin Stangel. (2014)
3,4-Diaminopyridine (amifampridine) for the treatment of Lambert–Eaton myasthenic syndrome. Expert Opinion on Orphan Drugs 2:3, pages 293-300.
Read now
Read now
Agnes van Sonderen, Paul W Wirtz, Jan JGM Verschuuren & Maarten J Titulaer. (2014) Treatment options for Lambert–Eaton myasthenic syndrome. Expert Opinion on Orphan Drugs 2:2, pages 159-167.
Read now
Read now
Sabine Lindquist & Martin Stangel. (2011) Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric Disease and Treatment 7, pages 341-349.
Read now
Read now
Articles from other publishers (27)
Hannah N. Tanner, Devan E. Atkins, Kimberly L. Bosh, Grace W. Breakfield, Sydney E. Daniels, Makayla J. Devore, Hailey E. Fite, Landys Z. Guo, Danielle K.J. Henry, Alana K. Kaffenb, Katherine S. Manning, Tatum E. Mowery, Cecilia L. Pankau, Malina E. Serrano, Yamaan Shakhashir, Ruth A. Ward, Aubrey H. Wehry & Robin L. Cooper. (2022) Effect of TEA and 4-AP on Primary Sensory Neurons in a Crustacean Model. Journal of Pharmacology and Toxicology 17:1, pages 14-27.
Crossref
Crossref
Jhan-Jie Peng, Shih-Han Lin, Yu-Tzu Liu, Hsin-Chieh Lin, Tsai-Ning Li & Chi-Kuang Yao. (2019) A circuit-dependent ROS feedback loop mediates glutamate excitotoxicity to sculpt the Drosophila motor system. eLife 8.
Crossref
Crossref
Marc Dooms & Maria Carvalho. (2018) Compounded medication for patients with rare diseases. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Youfen Xu, Katherine Halievski, Masahisa Katsuno, Hiroaki Adachi, Gen Sobue, S Marc Breedlove & Cynthia L Jordan. (2018) Pre-clinical symptoms of SBMA may not be androgen-dependent: implications from two SBMA mouse models. Human Molecular Genetics 27:14, pages 2425-2442.
Crossref
Crossref
Sofieke de Wilde, Maria G.H. de Jong, Alexander F. Lipka, Henk-Jan Guchelaar & Kirsten J.M. Schimmel. (2018) The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. European Journal of Pharmaceutical Sciences 114, pages 24-29.
Crossref
Crossref
Simona Portaro, Teresa Brizzi, Stefano Sinicropi, Alberto Cacciola, Maria Cristina De Cola, Alessia Bramanti, Demetrio Milardi, Antonino Lupica, Placido Bramanti, Antonio Toscano & Carmelo Rodolico. (2017) Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome. Medicine 96:38, pages e7839.
Crossref
Crossref
Benedikt Schoser, Bruno Eymard, Joe Datt & Renato Mantegazza. (2017) Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. Journal of Neurology 264:9, pages 1854-1863.
Crossref
Crossref
Peter E. Haroldsen, Zlatko Sisic, Joe Datt, Donald G. Musson & Gary Ingenito. (2017) Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function. Clinical Therapeutics 39:7, pages 1360-1370.
Crossref
Crossref
Elena E. Perez, Jordan S. Orange, Francisco Bonilla, Javier Chinen, Ivan K. Chinn, Morna Dorsey, Yehia El-Gamal, Terry O. Harville, Elham Hossny, Bruce Mazer, Robert Nelson, Elizabeth Secord, Stanley C. Jordan, E. Richard Stiehm, Ashley A. Vo & Mark Ballow. (2017) Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology 139:3, pages S1-S46.
Crossref
Crossref
Fiona Ng, Diana C. Lee, Leah A. Schrumpf, Mary E. Mazurek, Victoria Lee Lo, Sharleen K. Gill & Ricardo A. Maselli. (2017) Effect of 3,4-diaminopyridine at the murine neuromuscular junction. Muscle & Nerve 55:2, pages 223-231.
Crossref
Crossref
Shin J Oh, Natalya Shcherbakova, Anna Kostera-Pruszczyk, Mohammad Alsharabati, Mazen Dimachkie, Jose Munoz Blanco, Thomas Brannagan, Dragana Lavrnić, Perry B Shieh, Christophe Vial, Andreas Meisel, Samuel Komoly, Benedikt Schoser, Kumaraswamy Sivakumar & Yuen So. (2016)
Amifampridine phosphate (Firdapse
®
) is effective and safe in a phase 3 clinical trial in LEMS
. Muscle & Nerve 53:5, pages 717-725.
Crossref
Crossref
Peter E. Haroldsen, Donald G. Musson, Boyd Hanson, Adrian Quartel & Charles A. O’Neill. (2015) Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clinical Therapeutics 37:7, pages 1555-1563.
Crossref
Crossref
Peter E. Haroldsen, Marvin R. Garovoy, Donald G. Musson, Huiyu Zhou, Laurie Tsuruda, Boyd Hanson & Charles A. O'Neill. (2014)
Genetic variation in aryl
N
‐acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4‐diaminopyridine) phosphate
. Pharmacology Research & Perspectives 3:1.
Crossref
Crossref
Can Ebru Bekircan-Kurt. (2015) Voltage gated calcium channel antibody-related neurological diseases. World Journal of Clinical Cases 3:3, pages 293.
Crossref
Crossref
Mozaffar Asadi, Susan Torabi & Khosro Mohammadi. (2014) Synthesis, characterization, and thermodynamics of some new unsymmetrical Schiff bases of salicylaldehyde with 3,4-diaminopyridine and their cobalt(III) complexes. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 122, pages 676-681.
Crossref
Crossref
Jens Claassen, Rainer Spiegel, Roger Kalla, Mary Faldon, Christopher Kennard, Chotipat Danchaivijitr, Stanislaw Bardins, Nicole Rettinger, Erich Schneider, Thomas Brandt, Klaus Jahn, Julian Teufel, Michael Strupp & Adolfo Bronstein. (2013) A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. Journal of Neurology, Neurosurgery & Psychiatry 84:12, pages 1392-1399.
Crossref
Crossref
Bhupinder Sandhu, Marina S. Fonari, Kayla Sawyer & Tatiana V. Timofeeva. (2013) A series of crystalline solids composed of aminopyridines and succinic, fumaric, and sebacic acids. Journal of Molecular Structure 1052, pages 125-134.
Crossref
Crossref
Hua Wen, Michael W. Linhoff, Jeffrey M. Hubbard, Nathan R. Nelson, Donald Stensland, Julia Dallman, Gail Mandel & Paul Brehm. (2013) Zebrafish Calls for Reinterpretation for the Roles of P/Q Calcium Channels in Neuromuscular Transmission. The Journal of Neuroscience 33:17, pages 7384-7392.
Crossref
Crossref
John S. Stahl & Zachary C. Thumser. (2013) 4-Aminopyridine Does Not Enhance Flocculus Function in Tottering, a Mouse Model of Vestibulocerebellar Dysfunction and Ataxia. PLoS ONE 8:2, pages e57895.
Crossref
Crossref
Charlotte Vrinten, Stephanie S. Weinreich, Rob JPM Scholten & Jan JGM Verschuuren. (2012) 3,4-Diaminopyridine for myasthenia gravis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
D. M. Green, A. C. Jones & K. R. Brain. (2012) Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. Journal of Clinical Pharmacy and Therapeutics 37:1, pages 53-57.
Crossref
Crossref
Roy G Beran. 2012. Neurology for general practitioners. Neurology for general practitioners
171
186
.
Ramesh K. Khurana. 2012. Primer on the Autonomic Nervous System. Primer on the Autonomic Nervous System
593
596
.
A. Le Bail & L’. Smrčok. (2012)
Ab initio
structure determination of 3,4-diaminopyridin-1-ium dihydrogen phosphate
. Powder Diffraction 26:4, pages 321-325.
Crossref
Crossref
E Pasqualoni, F Aubart, B Brihaye, K Sacré, T Maisonobe, J-P Laissy, O Lidove & T Papo. (2011) Lambert–Eaton Myasthenic syndrome and follicular thymic hyperplasia in systemic lupus erythematosus. Lupus 20:7, pages 745-748.
Crossref
Crossref
Nils Erik Gilhus. (2011) Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases 2011, pages 1-5.
Crossref
Crossref
F. Hanisch & S. Zierz. 2012. Klinische Neurologie. Klinische Neurologie
303
318
.